ID   HEMH_HUMAN              Reviewed;         423 AA.
AC   P22830; A8KA72; Q8IXN1; Q8NAN0;
DT   01-AUG-1991, integrated into UniProtKB/Swiss-Prot.
DT   10-MAY-2005, sequence version 2.
DT   15-MAR-2017, entry version 185.
DE   RecName: Full=Ferrochelatase, mitochondrial;
DE            EC=4.99.1.1;
DE   AltName: Full=Heme synthase;
DE   AltName: Full=Protoheme ferro-lyase;
DE   Flags: Precursor;
GN   Name=FECH;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT GLN-96.
RX   PubMed=2260980; DOI=10.1016/S0006-291X(05)80099-3;
RA   Nakahashi Y., Taketani S., Okuda M., Inoue K., Tokunaga R.;
RT   "Molecular cloning and sequence analysis of cDNA encoding human
RT   ferrochelatase.";
RL   Biochem. Biophys. Res. Commun. 173:748-755(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT GLN-96.
RA   Gouya L.M., Martin C., Deybach J.-C., Puy H.V.;
RT   "Ferrochelatase: complete human gene sequence, amplifiable
RT   polymorphisms and molecular study of 12 families with erythropoietic
RT   protoporphyria.";
RL   Submitted (OCT-1999) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Placenta, and Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-22.
RX   PubMed=7983009;
RA   Tugores A., Magness S.T., Brenner D.A.;
RT   "A single promoter directs both housekeeping and erythroid
RT   preferential expression of the human ferrochelatase gene.";
RL   J. Biol. Chem. 269:30789-30797(1994).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-22.
RA   Di Pierro E., Martinez di Montemuros F., Moriondo V., Cappellini M.D.;
RT   "Molecular analysis of ferrochelatase gene in erythropoietic
RT   protoporphyria.";
RL   Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   CHARACTERIZATION, AND MUTAGENESIS.
RX   PubMed=8276824;
RA   Dailey H.A., Sellers V.M., Dailey T.A.;
RT   "Mammalian ferrochelatase. Expression and characterization of normal
RT   and two human protoporphyric ferrochelatases.";
RL   J. Biol. Chem. 269:390-395(1994).
RN   [10]
RP   IDENTIFICATION OF CYSTEINES COORDINATING THE 2FE-2S CLUSTER.
RX   PubMed=8973195; DOI=10.1021/bi9620114;
RA   Crouse B.R., Sellers V.M., Finnegan M.G., Dailey H.A., Johnson M.K.;
RT   "Site-directed mutagenesis and spectroscopic characterization of human
RT   ferrochelatase: identification of residues coordinating the [2Fe-2S]
RT   cluster.";
RL   Biochemistry 35:16222-16229(1996).
RN   [11]
RP   IDENTIFICATION OF CYSTEINES COORDINATING THE 2FE-2S CLUSTER.
RX   PubMed=9712849; DOI=10.1074/jbc.273.35.22311;
RA   Sellers V.M., Wang K.-F., Johnson M.K., Dailey H.A.;
RT   "Evidence that the fourth ligand to the 2Fe-2S cluster in animal
RT   ferrochelatase is a cysteine. Characterization of the enzyme from
RT   Drosophila melanogaster.";
RL   J. Biol. Chem. 273:22311-22316(1998).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS).
RX   PubMed=11175906; DOI=10.1038/84152;
RA   Wu C.-K., Dailey H.A., Rose J.P., Burden A., Sellers V.M., Wang B.-C.;
RT   "The 2.0 A structure of human ferrochelatase, the terminal enzyme of
RT   heme biosynthesis.";
RL   Nat. Struct. Biol. 8:156-160(2001).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 65-423 ALONE AND IN COMPLEX
RP   WITH PROTOPORPHYRIN IX, SUBUNIT, AND IRON-SULFUR CLUSTER.
RX   PubMed=17261801; DOI=10.1073/pnas.0606144104;
RA   Medlock A., Swartz L., Dailey T.A., Dailey H.A., Lanzilotta W.N.;
RT   "Substrate interactions with human ferrochelatase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:1789-1793(2007).
RN   [17]
RP   REVIEW ON VARIANTS EPP.
RX   PubMed=9211198; DOI=10.1023/A:1005317124985;
RA   Cox T.M.;
RT   "Erythropoietic protoporphyria.";
RL   J. Inherit. Metab. Dis. 20:258-269(1997).
RN   [18]
RP   VARIANTS EPP CYS-55 AND ILE-267.
RX   PubMed=1755842; DOI=10.1016/0006-291X(91)91231-Z;
RA   Lamoril J., Boulechfar S., de Verneuil H., Grandchamp B., Nordmann Y.,
RA   Deybach J.-C.;
RT   "Human erythropoietic protoporphyria: two point mutations in the
RT   ferrochelatase gene.";
RL   Biochem. Biophys. Res. Commun. 181:594-599(1991).
RN   [19]
RP   VARIANT EPP SER-417.
RX   PubMed=1376018;
RA   Brenner D.A., Didier J.M., Frasier F., Christensen S.R., Evans G.A.,
RA   Dailey H.A.;
RT   "A molecular defect in human protoporphyria.";
RL   Am. J. Hum. Genet. 50:1203-1210(1992).
RN   [20]
RP   VARIANT EPP GLY-362.
RX   PubMed=7910885; DOI=10.1016/S0140-6736(94)92525-9;
RA   Sarkany R.P.E., Alexander G.J.M.A., Cox T.M.;
RT   "Recessive inheritance of erythropoietic protoporphyria with liver
RT   failure.";
RL   Lancet 343:1394-1396(1994).
RN   [21]
RP   VARIANT EPP THR-186.
RX   PubMed=8757534; DOI=10.1046/j.1365-2141.1996.d01-1771.x;
RA   Imoto S., Tanizawa Y., Sata Y., Kaku K., Oka Y.;
RT   "A novel mutation in the ferrochelatase gene associated with
RT   erythropoietic protoporphyria.";
RL   Br. J. Haematol. 94:191-197(1996).
RN   [22]
RP   VARIANTS EPP LYS-71; PRO-151; HIS-191; THR-192; ILE-283; LYS-288;
RP   LEU-334 AND PHE-417 DEL, AND CHARACTERIZATION OF VARIANTS EPP LYS-71;
RP   PRO-151; HIS-191; THR-192; ILE-283; LYS-288; LEU-334 AND PHE-417 DEL.
RX   PubMed=9585598; DOI=10.1086/301870;
RA   Ruefenacht U.B., Gouya L., Schneider-Yin X., Puy H., Schaefer B.W.,
RA   Aquaron R., Nordmann Y., Minder E.I., Deybach J.-C.;
RT   "Systematic analysis of molecular defects in the ferrochelatase gene
RT   from patients with erythropoietic protoporphyria.";
RL   Am. J. Hum. Genet. 62:1341-1352(1998).
RN   [23]
RP   VARIANT EPP PRO-386.
RX   PubMed=9740232; DOI=10.1046/j.1523-1747.1998.00327.x;
RA   Gouya L., Schneider-Yin X., Rufenacht U., Herrero C., Lecha M.,
RA   Mascaro J.M., Puy H., Deybach J.-C., Minder E.I.;
RT   "Mutations in the ferrochelatase gene of four Spanish patients with
RT   erythropoietic protoporphyria.";
RL   J. Invest. Dermatol. 111:406-409(1998).
RN   [24]
RP   VARIANTS EPP SER-406; TYR-406 AND 408-LYS-SER--GLY-411, AND
RP   CHARACTERIZATION OF VARIANTS EPP SER-406; TYR-406 AND
RP   408-LYS-SER--GLY-411.
RX   PubMed=10942404;
RA   Schneider-Yin X., Gouya L., Dorsey M., Ruefenacht U., Deybach J.-C.,
RA   Ferreira G.C.;
RT   "Mutations in the iron-sulfur cluster ligands of the human
RT   ferrochelatase lead to erythropoietic protoporphyria.";
RL   Blood 96:1545-1549(2000).
RN   [25]
RP   VARIANT EPP ARG-182, AND CHARACTERIZATION OF VARIANT EPP ARG-182.
RX   PubMed=11375302;
RA   Ruefenacht U.B., Gregor A., Gouya L., Tarczynska-Nosal S.,
RA   Schneider-Yin X., Deybach J.-C.;
RT   "New missense mutation in the human ferrochelatase gene in a family
RT   with erythropoietic protoporphyria: functional studies and correlation
RT   of genotype and phenotype.";
RL   Clin. Chem. 47:1112-1113(2001).
RN   [26]
RP   VARIANT EPP ARG-62.
RX   PubMed=12063482; DOI=10.1067/mjd.2002.120460;
RA   Poh-Fitzpatrick M.B., Wang X., Anderson K.E., Bloomer J.R.,
RA   Bolwell B., Lichtin A.E.;
RT   "Erythropoietic protoporphyria: altered phenotype after bone marrow
RT   transplantation for myelogenous leukemia in a patient heteroallelic
RT   for ferrochelatase gene mutations.";
RL   J. Am. Acad. Dermatol. 46:861-866(2002).
RN   [27]
RP   VARIANTS EPP LYS-178 AND LEU-334.
RX   PubMed=12601550; DOI=10.1007/s100380300009;
RA   Wiman A., Floderus Y., Harper P.;
RT   "Novel mutations and phenotypic effect of the splice site modulator
RT   IVS3-48C in nine Swedish families with erythropoietic
RT   protoporphyria.";
RL   J. Hum. Genet. 48:70-76(2003).
RN   [28]
RP   VARIANTS EPP LEU-139; TYR-236; LEU-260 AND ASN-379, AND
RP   CHARACTERIZATION OF VARIANTS EPP LEU-139; TYR-236; LEU-260 AND
RP   ASN-379.
RX   PubMed=15286165; DOI=10.1136/jmg.2003.016121;
RA   Whatley S.D., Mason N.G., Khan M., Zamiri M., Badminton M.N.,
RA   Missaoui W.N., Dailey T.A., Dailey H.A., Douglas W.S.,
RA   Wainwright N.J., Elder G.H.;
RT   "Autosomal recessive erythropoietic protoporphyria in the United
RT   Kingdom: prevalence and relationship to liver disease.";
RL   J. Med. Genet. 41:E105-E105(2004).
RN   [29]
RP   VARIANT EPP LEU-264.
RX   PubMed=17196862; DOI=10.1016/j.ymgme.2006.10.012;
RA   Aurizi C., Schneider-Yin X., Sorge F., Macri A., Minder E.I.,
RA   Biolcati G.;
RT   "Heterogeneity of mutations in the ferrochelatase gene in Italian
RT   patients with erythropoietic protoporphyria.";
RL   Mol. Genet. Metab. 90:402-407(2007).
CC   -!- FUNCTION: Catalyzes the ferrous insertion into protoporphyrin IX.
CC   -!- CATALYTIC ACTIVITY: Protoheme + 2 H(+) = protoporphyrin + Fe(2+).
CC   -!- COFACTOR:
CC       Name=[2Fe-2S] cluster; Xref=ChEBI:CHEBI:49601;
CC       Note=Binds 1 [2Fe-2S] cluster.;
CC   -!- ENZYME REGULATION: Inhibited by nitric oxide (NO). The 2Fe-2S
CC       cluster could act as a NO sensor.
CC   -!- PATHWAY: Porphyrin-containing compound metabolism; protoheme
CC       biosynthesis; protoheme from protoporphyrin-IX: step 1/1.
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:17261801}.
CC   -!- INTERACTION:
CC       O00264:PGRMC1; NbExp=3; IntAct=EBI-1390356, EBI-1045534;
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane; Peripheral
CC       membrane protein; Matrix side.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P22830-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P22830-2; Sequence=VSP_041208;
CC   -!- DISEASE: Erythropoietic protoporphyria (EPP) [MIM:177000]: A form
CC       of porphyria. Porphyrias are inherited defects in the biosynthesis
CC       of heme, resulting in the accumulation and increased excretion of
CC       porphyrins or porphyrin precursors. They are classified as
CC       erythropoietic or hepatic, depending on whether the enzyme
CC       deficiency occurs in red blood cells or in the liver.
CC       Erythropoietic protoporphyria is marked by excessive
CC       protoporphyrin in erythrocytes, plasma, liver and feces, and by
CC       widely varying photosensitive skin changes ranging from a burning
CC       or pruritic sensation to erythema, edema and wheals.
CC       {ECO:0000269|PubMed:10942404, ECO:0000269|PubMed:11375302,
CC       ECO:0000269|PubMed:12063482, ECO:0000269|PubMed:12601550,
CC       ECO:0000269|PubMed:1376018, ECO:0000269|PubMed:15286165,
CC       ECO:0000269|PubMed:17196862, ECO:0000269|PubMed:1755842,
CC       ECO:0000269|PubMed:7910885, ECO:0000269|PubMed:8757534,
CC       ECO:0000269|PubMed:9211198, ECO:0000269|PubMed:9585598,
CC       ECO:0000269|PubMed:9740232}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the ferrochelatase family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Ferrochelatase entry;
CC       URL="https://en.wikipedia.org/wiki/Ferrochelatase";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D00726; BAA00628.1; -; mRNA.
DR   EMBL; AJ250235; CAB65962.1; -; Genomic_DNA.
DR   EMBL; BT019958; AAV38761.1; -; mRNA.
DR   EMBL; AK092416; BAC03882.1; -; mRNA.
DR   EMBL; AK292937; BAF85626.1; -; mRNA.
DR   EMBL; CH471096; EAW63046.1; -; Genomic_DNA.
DR   EMBL; BC039841; AAH39841.2; -; mRNA.
DR   EMBL; L36178; AAA64787.1; -; Genomic_DNA.
DR   EMBL; AF495859; AAM18070.1; -; Genomic_DNA.
DR   CCDS; CCDS11964.1; -. [P22830-1]
DR   CCDS; CCDS32836.1; -. [P22830-2]
DR   PIR; A36403; A36403.
DR   RefSeq; NP_000131.2; NM_000140.3. [P22830-1]
DR   RefSeq; NP_001012533.1; NM_001012515.2. [P22830-2]
DR   UniGene; Hs.365365; -.
DR   PDB; 1HRK; X-ray; 2.00 A; A/B=65-423.
DR   PDB; 2HRC; X-ray; 1.70 A; A/B=65-423.
DR   PDB; 2HRE; X-ray; 2.50 A; A/B/C/D=65-423.
DR   PDB; 2PNJ; X-ray; 2.35 A; A/B=65-423.
DR   PDB; 2PO5; X-ray; 2.20 A; A/B=65-423.
DR   PDB; 2PO7; X-ray; 2.20 A; A/B=65-423.
DR   PDB; 2QD1; X-ray; 2.20 A; A/B/C/D=65-423.
DR   PDB; 2QD2; X-ray; 2.20 A; A/B=65-423.
DR   PDB; 2QD3; X-ray; 2.20 A; A/B=65-423.
DR   PDB; 2QD4; X-ray; 2.00 A; A/B=65-423.
DR   PDB; 2QD5; X-ray; 2.30 A; A/B=65-423.
DR   PDB; 3AQI; X-ray; 1.70 A; A/B=65-423.
DR   PDB; 3HCN; X-ray; 1.60 A; A/B=65-423.
DR   PDB; 3HCO; X-ray; 1.80 A; A/B=65-423.
DR   PDB; 3HCP; X-ray; 2.00 A; A/B=65-423.
DR   PDB; 3HCR; X-ray; 2.20 A; A/B=65-423.
DR   PDB; 3W1W; X-ray; 2.01 A; A/B=61-423.
DR   PDB; 4F4D; X-ray; 1.80 A; A/B=65-423.
DR   PDB; 4KLA; X-ray; 2.60 A; A/B=65-423.
DR   PDB; 4KLC; X-ray; 2.40 A; A/B=65-423.
DR   PDB; 4KLR; X-ray; 2.18 A; A/B=65-423.
DR   PDB; 4KMM; X-ray; 2.60 A; A/B=65-423.
DR   PDB; 4MK4; X-ray; 2.50 A; A/B=65-423.
DR   PDBsum; 1HRK; -.
DR   PDBsum; 2HRC; -.
DR   PDBsum; 2HRE; -.
DR   PDBsum; 2PNJ; -.
DR   PDBsum; 2PO5; -.
DR   PDBsum; 2PO7; -.
DR   PDBsum; 2QD1; -.
DR   PDBsum; 2QD2; -.
DR   PDBsum; 2QD3; -.
DR   PDBsum; 2QD4; -.
DR   PDBsum; 2QD5; -.
DR   PDBsum; 3AQI; -.
DR   PDBsum; 3HCN; -.
DR   PDBsum; 3HCO; -.
DR   PDBsum; 3HCP; -.
DR   PDBsum; 3HCR; -.
DR   PDBsum; 3W1W; -.
DR   PDBsum; 4F4D; -.
DR   PDBsum; 4KLA; -.
DR   PDBsum; 4KLC; -.
DR   PDBsum; 4KLR; -.
DR   PDBsum; 4KMM; -.
DR   PDBsum; 4MK4; -.
DR   ProteinModelPortal; P22830; -.
DR   SMR; P22830; -.
DR   BioGrid; 108526; 43.
DR   DIP; DIP-39632N; -.
DR   IntAct; P22830; 33.
DR   STRING; 9606.ENSP00000372326; -.
DR   DrugBank; DB02659; Cholic Acid.
DR   iPTMnet; P22830; -.
DR   PhosphoSitePlus; P22830; -.
DR   BioMuta; FECH; -.
DR   DMDM; 85701348; -.
DR   EPD; P22830; -.
DR   MaxQB; P22830; -.
DR   PaxDb; P22830; -.
DR   PeptideAtlas; P22830; -.
DR   PRIDE; P22830; -.
DR   DNASU; 2235; -.
DR   Ensembl; ENST00000262093; ENSP00000262093; ENSG00000066926. [P22830-1]
DR   Ensembl; ENST00000382873; ENSP00000372326; ENSG00000066926. [P22830-2]
DR   GeneID; 2235; -.
DR   KEGG; hsa:2235; -.
DR   UCSC; uc002lgp.5; human. [P22830-1]
DR   CTD; 2235; -.
DR   DisGeNET; 2235; -.
DR   GeneCards; FECH; -.
DR   GeneReviews; FECH; -.
DR   HGNC; HGNC:3647; FECH.
DR   HPA; HPA044100; -.
DR   HPA; HPA048177; -.
DR   MalaCards; FECH; -.
DR   MIM; 177000; phenotype.
DR   MIM; 612386; gene.
DR   neXtProt; NX_P22830; -.
DR   OpenTargets; ENSG00000066926; -.
DR   Orphanet; 79278; Erythropoietic protoporphyria.
DR   PharmGKB; PA28087; -.
DR   eggNOG; KOG1321; Eukaryota.
DR   eggNOG; COG0276; LUCA.
DR   GeneTree; ENSGT00390000016258; -.
DR   HOGENOM; HOG000060727; -.
DR   HOVERGEN; HBG051898; -.
DR   InParanoid; P22830; -.
DR   KO; K01772; -.
DR   OMA; LPIQNKL; -.
DR   OrthoDB; EOG091G0850; -.
DR   PhylomeDB; P22830; -.
DR   TreeFam; TF300859; -.
DR   BioCyc; MetaCyc:HS00891-MONOMER; -.
DR   BRENDA; 4.99.1.1; 2681.
DR   Reactome; R-HSA-189451; Heme biosynthesis.
DR   SABIO-RK; P22830; -.
DR   UniPathway; UPA00252; UER00325.
DR   ChiTaRS; FECH; human.
DR   EvolutionaryTrace; P22830; -.
DR   GeneWiki; Ferrochelatase; -.
DR   GenomeRNAi; 2235; -.
DR   PRO; PR:P22830; -.
DR   Proteomes; UP000005640; Chromosome 18.
DR   Bgee; ENSG00000066926; -.
DR   CleanEx; HS_FECH; -.
DR   ExpressionAtlas; P22830; baseline and differential.
DR   Genevisible; P22830; HS.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome.
DR   GO; GO:0051537; F:2 iron, 2 sulfur cluster binding; IEA:UniProtKB-KW.
DR   GO; GO:0004325; F:ferrochelatase activity; IDA:BHF-UCL.
DR   GO; GO:0008198; F:ferrous iron binding; TAS:ProtInc.
DR   GO; GO:0071549; P:cellular response to dexamethasone stimulus; IEA:Ensembl.
DR   GO; GO:0006091; P:generation of precursor metabolites and energy; TAS:ProtInc.
DR   GO; GO:0006783; P:heme biosynthetic process; TAS:Reactome.
DR   GO; GO:0046501; P:protoporphyrinogen IX metabolic process; IDA:BHF-UCL.
DR   GO; GO:0046685; P:response to arsenic-containing substance; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0017085; P:response to insecticide; IEA:Ensembl.
DR   GO; GO:0010288; P:response to lead ion; IEA:Ensembl.
DR   GO; GO:0009416; P:response to light stimulus; TAS:ProtInc.
DR   GO; GO:0051597; P:response to methylmercury; IEA:Ensembl.
DR   GO; GO:0070541; P:response to platinum ion; IEA:Ensembl.
DR   CDD; cd00419; Ferrochelatase_C; 1.
DR   CDD; cd03411; Ferrochelatase_N; 1.
DR   HAMAP; MF_00323; Ferrochelatase; 1.
DR   InterPro; IPR001015; Ferrochelatase.
DR   InterPro; IPR019772; Ferrochelatase_AS.
DR   InterPro; IPR033644; Ferrochelatase_C.
DR   InterPro; IPR033659; Ferrochelatase_N.
DR   PANTHER; PTHR11108; PTHR11108; 1.
DR   Pfam; PF00762; Ferrochelatase; 1.
DR   TIGRFAMs; TIGR00109; hemH; 1.
DR   PROSITE; PS00534; FERROCHELATASE; 1.
PE   1: Evidence at protein level;
KW   2Fe-2S; 3D-structure; Acetylation; Alternative splicing;
KW   Complete proteome; Disease mutation; Heme biosynthesis; Iron;
KW   Iron-sulfur; Lyase; Membrane; Metal-binding; Mitochondrion;
KW   Mitochondrion inner membrane; Polymorphism; Porphyrin biosynthesis;
KW   Reference proteome; Transit peptide.
FT   TRANSIT       1     54       Mitochondrion. {ECO:0000255}.
FT   CHAIN        55    423       Ferrochelatase, mitochondrial.
FT                                /FTId=PRO_0000008873.
FT   ACT_SITE    230    230
FT   ACT_SITE    383    383
FT   METAL       196    196       Iron-sulfur (2Fe-2S).
FT   METAL       403    403       Iron-sulfur (2Fe-2S).
FT   METAL       406    406       Iron-sulfur (2Fe-2S).
FT   METAL       411    411       Iron-sulfur (2Fe-2S).
FT   MOD_RES      57     57       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P22315}.
FT   MOD_RES     138    138       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:P22315}.
FT   MOD_RES     415    415       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P22315}.
FT   MOD_RES     415    415       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P22315}.
FT   VAR_SEQ      64     64       K -> KRYESNI (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_041208.
FT   VARIANT      55     55       G -> C (in EPP; dbSNP:rs3848519).
FT                                {ECO:0000269|PubMed:1755842}.
FT                                /FTId=VAR_002383.
FT   VARIANT      62     62       P -> R (in EPP; dbSNP:rs150830931).
FT                                {ECO:0000269|PubMed:12063482}.
FT                                /FTId=VAR_030553.
FT   VARIANT      71     71       I -> K (in EPP; enzyme totally inactive).
FT                                {ECO:0000269|PubMed:9585598}.
FT                                /FTId=VAR_030554.
FT   VARIANT      96     96       R -> Q (in dbSNP:rs1041951).
FT                                {ECO:0000269|PubMed:2260980,
FT                                ECO:0000269|Ref.2}.
FT                                /FTId=VAR_012028.
FT   VARIANT     139    139       Q -> L (in EPP; autosomal recessive EPP;
FT                                enzyme retains 18% of activity).
FT                                {ECO:0000269|PubMed:15286165}.
FT                                /FTId=VAR_030555.
FT   VARIANT     151    151       S -> P (in EPP; enzyme totally inactive).
FT                                {ECO:0000269|PubMed:9585598}.
FT                                /FTId=VAR_030556.
FT   VARIANT     178    178       E -> K (in EPP).
FT                                {ECO:0000269|PubMed:12601550}.
FT                                /FTId=VAR_030557.
FT   VARIANT     182    182       L -> R (in EPP; enzyme totally inactive).
FT                                {ECO:0000269|PubMed:11375302}.
FT                                /FTId=VAR_030558.
FT   VARIANT     186    186       I -> T (in EPP).
FT                                {ECO:0000269|PubMed:8757534}.
FT                                /FTId=VAR_002384.
FT   VARIANT     191    191       Y -> H (in EPP; enzyme retains 72% of
FT                                activity). {ECO:0000269|PubMed:9585598}.
FT                                /FTId=VAR_030559.
FT   VARIANT     192    192       P -> T (in EPP; enzyme totally inactive).
FT                                {ECO:0000269|PubMed:9585598}.
FT                                /FTId=VAR_030560.
FT   VARIANT     236    236       C -> Y (in EPP; enzyme retains 12% of
FT                                activity; dbSNP:rs761962617).
FT                                {ECO:0000269|PubMed:15286165}.
FT                                /FTId=VAR_030561.
FT   VARIANT     260    260       F -> L (in EPP; autosomal recessive EPP;
FT                                enzyme retains 52% of activity).
FT                                {ECO:0000269|PubMed:15286165}.
FT                                /FTId=VAR_030562.
FT   VARIANT     264    264       S -> L (in EPP).
FT                                {ECO:0000269|PubMed:17196862}.
FT                                /FTId=VAR_054629.
FT   VARIANT     267    267       M -> I (in EPP; unchanged activity; but
FT                                increased thermolability;
FT                                dbSNP:rs118204037).
FT                                {ECO:0000269|PubMed:1755842}.
FT                                /FTId=VAR_002385.
FT   VARIANT     283    283       T -> I (in EPP; enzyme almost inactive).
FT                                {ECO:0000269|PubMed:9585598}.
FT                                /FTId=VAR_030563.
FT   VARIANT     288    288       M -> K (in EPP; enzyme totally inactive).
FT                                {ECO:0000269|PubMed:9585598}.
FT                                /FTId=VAR_030564.
FT   VARIANT     334    334       P -> L (in EPP; autosomal recessive EPP;
FT                                enzyme retains 19% of activity;
FT                                dbSNP:rs150146721).
FT                                {ECO:0000269|PubMed:12601550,
FT                                ECO:0000269|PubMed:9585598}.
FT                                /FTId=VAR_030565.
FT   VARIANT     362    362       V -> G (in EPP; dbSNP:rs118204040).
FT                                {ECO:0000269|PubMed:7910885}.
FT                                /FTId=VAR_030566.
FT   VARIANT     379    379       K -> N (in EPP; autosomal recessive EPP;
FT                                enzyme retains 37% of activity).
FT                                {ECO:0000269|PubMed:15286165}.
FT                                /FTId=VAR_030567.
FT   VARIANT     386    386       H -> P (in EPP; loss of activity).
FT                                {ECO:0000269|PubMed:9740232}.
FT                                /FTId=VAR_002386.
FT   VARIANT     406    406       C -> S (in EPP; enzyme almost inactive).
FT                                {ECO:0000269|PubMed:10942404}.
FT                                /FTId=VAR_030568.
FT   VARIANT     406    406       C -> Y (in EPP; enzyme almost inactive).
FT                                {ECO:0000269|PubMed:10942404}.
FT                                /FTId=VAR_030569.
FT   VARIANT     408    411       NPVC -> KSVG (in EPP; no detectable
FT                                enzymatic activity).
FT                                /FTId=VAR_030570.
FT   VARIANT     417    417       F -> S (in EPP; reduced activity;
FT                                dbSNP:rs118204039).
FT                                {ECO:0000269|PubMed:1376018}.
FT                                /FTId=VAR_002387.
FT   VARIANT     417    417       Missing (in EPP; enzyme totally
FT                                inactive). {ECO:0000269|PubMed:9585598}.
FT                                /FTId=VAR_030571.
FT   MUTAGEN     196    196       C->S: Loss of activity.
FT                                {ECO:0000269|PubMed:8276824}.
FT   MUTAGEN     360    360       C->S: No loss of activity.
FT                                {ECO:0000269|PubMed:8276824}.
FT   MUTAGEN     395    395       C->S: No loss of activity.
FT                                {ECO:0000269|PubMed:8276824}.
FT   MUTAGEN     403    403       C->D,H: Loss of activity.
FT                                {ECO:0000269|PubMed:8276824}.
FT   MUTAGEN     406    406       C->D,H,S: Loss of activity.
FT                                {ECO:0000269|PubMed:8276824}.
FT   MUTAGEN     411    411       C->H,S: Loss of activity.
FT                                {ECO:0000269|PubMed:8276824}.
FT   MUTAGEN     417    417       F->L: Decreased activity.
FT                                {ECO:0000269|PubMed:8276824}.
FT   MUTAGEN     417    417       F->Y,W: Greatly reduced activity.
FT                                {ECO:0000269|PubMed:8276824}.
FT   CONFLICT    228    228       P -> S (in Ref. 4; BAC03882).
FT                                {ECO:0000305}.
FT   STRAND       69     75       {ECO:0000244|PDB:3HCN}.
FT   HELIX        82     84       {ECO:0000244|PDB:3HCN}.
FT   HELIX        85     93       {ECO:0000244|PDB:3HCN}.
FT   TURN         96     98       {ECO:0000244|PDB:3HCN}.
FT   HELIX       104    125       {ECO:0000244|PDB:3HCN}.
FT   HELIX       132    150       {ECO:0000244|PDB:3HCN}.
FT   HELIX       152    154       {ECO:0000244|PDB:3HCN}.
FT   STRAND      156    169       {ECO:0000244|PDB:3HCN}.
FT   HELIX       170    179       {ECO:0000244|PDB:3HCN}.
FT   STRAND      183    190       {ECO:0000244|PDB:3HCN}.
FT   TURN        196    198       {ECO:0000244|PDB:3HCN}.
FT   HELIX       199    212       {ECO:0000244|PDB:3HCN}.
FT   STRAND      218    224       {ECO:0000244|PDB:3HCN}.
FT   HELIX       231    245       {ECO:0000244|PDB:3HCN}.
FT   TURN        250    252       {ECO:0000244|PDB:3HCN}.
FT   HELIX       253    255       {ECO:0000244|PDB:3HCN}.
FT   STRAND      257    263       {ECO:0000244|PDB:3HCN}.
FT   HELIX       267    270       {ECO:0000244|PDB:3HCN}.
FT   TURN        271    273       {ECO:0000244|PDB:3HCN}.
FT   HELIX       276    290       {ECO:0000244|PDB:3HCN}.
FT   TURN        291    293       {ECO:0000244|PDB:3HCN}.
FT   STRAND      297    302       {ECO:0000244|PDB:3HCN}.
FT   STRAND      306    308       {ECO:0000244|PDB:2HRC}.
FT   STRAND      310    314       {ECO:0000244|PDB:3HCN}.
FT   HELIX       315    324       {ECO:0000244|PDB:3HCN}.
FT   STRAND      329    333       {ECO:0000244|PDB:3HCN}.
FT   HELIX       345    348       {ECO:0000244|PDB:3HCN}.
FT   HELIX       350    359       {ECO:0000244|PDB:3HCN}.
FT   STRAND      364    367       {ECO:0000244|PDB:3HCN}.
FT   STRAND      371    373       {ECO:0000244|PDB:4KLR}.
FT   HELIX       375    391       {ECO:0000244|PDB:3HCN}.
FT   HELIX       397    400       {ECO:0000244|PDB:3HCN}.
FT   HELIX       410    419       {ECO:0000244|PDB:3HCN}.
SQ   SEQUENCE   423 AA;  47862 MW;  3FD50965E8DEABCE CRC64;
     MRSLGANMAA ALRAAGVLLR DPLASSSWRV CQPWRWKSGA AAAAVTTETA QHAQGAKPQV
     QPQKRKPKTG ILMLNMGGPE TLGDVHDFLL RLFLDRDLMT LPIQNKLAPF IAKRRTPKIQ
     EQYRRIGGGS PIKIWTSKQG EGMVKLLDEL SPNTAPHKYY IGFRYVHPLT EEAIEEMERD
     GLERAIAFTQ YPQYSCSTTG SSLNAIYRYY NQVGRKPTMK WSTIDRWPTH HLLIQCFADH
     ILKELDHFPL EKRSEVVILF SAHSLPMSVV NRGDPYPQEV SATVQKVMER LEYCNPYRLV
     WQSKVGPMPW LGPQTDESIK GLCERGRKNI LLVPIAFTSD HIETLYELDI EYSQVLAKEC
     GVENIRRAES LNGNPLFSKA LADLVHSHIQ SNELCSKQLT LSCPLCVNPV CRETKSFFTS
     QQL
//
